Viridian's Lumvoa Approved for Thyroid Eye Disease, Posing Challenge to Amgen's Tepezza

FDA Approves Viridian's Lumvoa for Thyroid Eye Disease

Viridian Therapeutics received FDA approval for Lumvoa to treat thyroid eye disease, positioning it as a strong competitor to Amgen's Tepezza. Lumvoa offers a shorter treatment duration with five infusions over 30-40 minutes, compared to Tepezza's eight infusions over 90 minutes. A key differentiator is Lumvoa's label, which covers both active and chronic forms of the autoimmune condition. Analysts project Lumvoa could achieve revenues of approximately $738 million by 2035, with its pricing on par with Tepezza at around $450,000, aiming to expand the treated TED market.

• Lumvoa's treatment regimen involves five infusions, each lasting 30 to 40 minutes, administered once every three weeks. This is a significant improvement over Amgen's Tepezza, which requires eight infusions, each taking up to 90 minutes, also given every three weeks. This shorter and less frequent administration could enhance patient convenience and physician adoption.
• A crucial competitive edge for Lumvoa is its FDA-approved label, which includes the treatment of both active and chronic thyroid eye disease. In contrast, Tepezza's label is primarily for active TED. This broader indication allows Lumvoa to address a wider patient population, potentially expanding the overall treated market for the condition.
• Analysts project Lumvoa could generate revenues of approximately $738 million by 2035, despite an anticipated slow initial revenue build-up. The drug's pricing is set at about $450,000, aligning with Tepezza's cost, which is expected to support patient access and market penetration. This strategic pricing, combined with its clinical profile, aims to capture a substantial share of the thyroid eye disease market.

Addressing the Unmet Needs in Thyroid Eye Disease Treatment

Current treatment approaches for Thyroid Eye Disease (TED) face significant limitations that span clinical efficacy, disease heterogeneity, and patient-reported outcomes. Even with advances such as teprotumumab, meaningful gaps remain in durability of response, diagnostic precision, and long-term quality of life (QoL) restoration.

• Incomplete QoL restoration: Overall QoL remains persistently reduced compared to a matched general population even after treatment of hyperthyroidism, driven by residual tiredness, mental fatigue, ophthalmological symptoms, concerns about levothyroxine substitution, and weight gain.

• Teprotumumab relapse dynamics vary by disease phase: Active-phase patients experience earlier (mean 8.2 vs. 12.3 months), more prolonged (mean 11.1 vs. 4.2 months, p = 0.000035), and more severe relapses than those treated in the stable phase — including at least one case of new-onset optic neuropathy — underscoring the need for phase-specific counseling and monitoring protocols.

• Diagnostic complexity in atypical presentations: Euthyroid Graves ophthalmopathy with negative antibodies (EGONA) presents a diagnostic challenge, as normal thyroid levels and absent antibodies mean diagnosis relies primarily on clinical signs and imaging; prognosis varies depending on whether thyroid imbalances or antibodies emerge over time.

• Concurrent comorbidities complicate management: The co-occurrence of TED and myasthenia gravis (MG), though rare (0.23% of 6,576 TED patients), produces overlapping clinical features that can obscure diagnosis and delay appropriate treatment.

• Insufficient objective data on newer therapeutic modalities: For emerging interventions including radiofrequency ablation and molecular targeted immunotherapies, there is a notable dearth of objective QoL outcome data, limiting evidence-based treatment selection.

• Weight gain as an underappreciated disease burden: Excessive weight gain has been identified as a recently highlighted contributor and independent predictor of poor QoL in hyperthyroidism patients — a concern amplified by the global obesity epidemic that warrants dedicated attention in treatment planning.

• Lack of randomized controlled evidence for QoL-focused interventions: There remains a critical need for randomized controlled studies to guide practitioners on which pharmacological and non-pharmacological interventions deliver the best long-term QoL outcomes, alongside development of improved assessment tools capable of capturing the full spectrum of patient concerns.

Reshaping the Thyroid Eye Disease Treatment Landscape with Lumvoa

Over the past five years, the thyroid eye disease (TED) treatment landscape has undergone a fundamental transformation, driven primarily by the clinical validation of teprotumumab — the first and only FDA-approved biologic therapy for TED. As an IGF-1R monoclonal antibody inhibitor, teprotumumab was approved in January 2020 on the basis of two randomized, double-masked, placebo-controlled trials enrolling patients with active, moderate-to-severe TED (CAS ≥ 4). Subsequent meta-analyses and real-world studies have reinforced this efficacy signal at scale: a 2026 meta-analysis of seven RCTs comprising 438 participants demonstrated statistically significant improvements in proptosis response (RR 6.87; 95% CI 3.32–14.24), overall response (RR 7.82; 95% CI 3.36–18.18), mean proptosis reduction (−2.46 mm; 95% CI −2.96 to −1.96), diplopia response (RR 1.85; 95% CI 1.28–2.68), CAS ≤1 (RR 3.39; 95% CI 2.41–4.78), and GO-QOL overall score improvement (MD 10.87; 95% CI 9.91–11.83). A 2022 network meta-analysis of 23 studies (1,047 patients) further positioned teprotumumab as the most effective single agent for proptosis reduction, second only to combined IVGC plus orbital radiotherapy in overall response rate rankings. The OPTIC-X open-label extension study confirmed durability and retreatment utility, with 89.2% of prior placebo-treated patients achieving proptosis response and 90.6% maintaining response at week 48.

Despite this therapeutic advance, evolving trial data have introduced important nuance around safety, durability, and access. Key safety signals from meta-analytic data include elevated risks of hyperglycemia (RR 2.82), muscle spasms (RR 3.83), dry skin (RR 6.54), and hearing impairment (RR 3.74) — with ototoxicity emerging as a potentially serious long-term concern warranting baseline audiometric evaluation. Endocrine monitoring has also become increasingly relevant, as a prospective cohort study of 46 teprotumumab-treated patients demonstrated a significant post-treatment decline in free thyroxine levels (1.7 ± 1.2 to 1.3 ± 0.4; p = 0.049), with over half of patients requiring antithyroid medication adjustments during therapy. Furthermore, up to 75% of patients may experience proptosis regression following treatment discontinuation, raising unresolved questions about retreatment thresholds and long-term disease control. A comparative retrospective study from the UAE found teprotumumab produced greater mean proptosis reduction than tocilizumab (2.55 ± 1.01 mm vs. 2.07 ± 1.07 mm; p = 0.04) with lower recurrence rates, though the cost burden — approximately USD 360,000 for a full eight-infusion course — continues to limit global access.

In parallel, the broader treatment armamentarium has been refined by new evidence repositioning established and emerging agents. Intravenous glucocorticoids (IVGCs) remain the most consistently supported first-line therapy, with favorable tolerability at cumulative doses below 8 g and strong inflammatory control, though incomplete responses occur in up to 55% of patients. Tocilizumab has been increasingly evaluated as a second-line option in glucocorticoid-resistant cases, with a prospective two-center study reporting CAS reductions ≥ 2 points in 75–100% of patients and proptosis reduction ≥ 2 mm in approximately 58–59%. Rituximab has demonstrated the capacity to durably modify disease natural history, and mycophenolate mofetil has emerged as the most reliable non-biologic immunosuppressive agent. A 2026 systematic review of 58 studies concluded that IGF-1R-targeted therapy offers the most comprehensive efficacy profile across key clinical domains, though IVGCs remain the preferred first-line standard. Emerging agents — including subcutaneous IGF-1R inhibitors (lonigutamab, VRDN-002/003), oral linsitinib, and FcRn-blocking antibodies — are advancing in clinical investigation, alongside novel conceptual frameworks distinguishing disease-modulating from disease-modifying therapeutic objectives.

Lumvoa's Entry: Reshaping the TED Treatment Landscape

The recent FDA approval of Lumvoa marks a pivotal moment for the thyroid eye disease (TED) treatment landscape, signaling a new era of competition and expanded options for patients grappling with this debilitating autoimmune condition. For years, patients and clinicians have sought more effective and less burdensome alternatives to traditional steroids and rehabilitative surgery, which often fail to restore normal orbital anatomy or prevent recurrence. The introduction of the first targeted biologic therapy represented a paradigm shift, offering significant improvements in proptosis, inflammation, and quality of life.

Lumvoa's entry as a second approved targeted therapy is set to intensify this evolving market. Its key advantages—a significantly shorter infusion duration and an explicit label for both active and chronic forms of TED—directly address critical unmet needs. This convenience factor could be a powerful driver for patient preference and adherence, simplifying what has historically been a complex and lengthy treatment journey. By explicitly covering chronic disease, Lumvoa also broadens the scope of treatable patients, potentially offering a targeted medical option where previously only surgery or less effective interventions were considered.

However, this new chapter also brings important considerations:

• Safety Profile: As with any new targeted therapy, particularly in a class with known side effects like hyperglycemia, hearing impairment, and muscle spasms, Lumvoa's long-term safety profile will be under close observation, especially as it is used in a broader patient population.

• Market Access and Cost: While Lumvoa's pricing aligns with the existing therapy, the high cost of these innovative treatments remains a significant concern for healthcare systems and patients, potentially impacting access and reimbursement decisions.

• Evolving Research: The field of TED is dynamic, with ongoing research into new therapeutic targets and personalized medicine approaches. Future developments could further refine treatment paradigms, necessitating continuous evaluation of Lumvoa's position and value proposition.

Ultimately, Lumvoa's approval represents a positive step forward, offering more choice and convenience for TED patients. Its success will hinge on demonstrating sustained real-world benefits, managing its safety profile, and navigating the complex economic realities of high-cost specialty medications in an increasingly competitive and innovative therapeutic area.